Literature DB >> 9369276

Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells.

M Shichiri1, H Kato, F Marumo, Y Hirata.   

Abstract

Endothelin-1 (ET-1), an endothelium-derived vasoactive peptide, functions as a potent vasoconstrictor as well as mitogen. We show here a novel role for ET-1 as an apoptosis survival factor for cultured rat endothelial cells. When we rendered endothelial cells obtained from rat aorta quiescent by serum starvation, significant portions of cultured cells underwent apoptotic death as demonstrated by nucleosomal laddering on agarose gel electrophoresis, flow cytometry analysis with FACS, and the TdT-mediated dUTP biotin nick-end labeling (TUNEL) method. ET-1 dose-dependently (10[-12] to 10[-6] mol/L) suppressed the apoptosis induced by serum starvation. The ET(B) receptor antagonist (BQ788; 10[-6] mol/L) and ET(A/B) receptor antagonists (PD142893 and PD145065; 10[-6] mol/L), but not the ET(A) receptor antagonist (BQ123; 10[-6] mol/L), blocked the apoptosis protective effect of 10[-7] mol/L ET-1. Nonimmune rabbit serum reduced the apoptotic event induced by serum deprivation, whereas neutralization of endogenous ET-1 by polyclonal anti-ET-1 antiserum abrogated this protective effect. The ET(B) receptor antagonist (BQ788; 10[-8] to 10[-6] mol/L), but not the ET(A) receptor antagonist (BQ123; 10[-8] to 10[-6] mol/L), significantly inhibited proliferation of endothelial cells. These data suggest that ET-1, as well as mitogen, functions as an apoptosis survival factor for endothelial cells in an autocrine/paracrine manner via the ET(B) receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369276     DOI: 10.1161/01.hyp.30.5.1198

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  39 in total

1.  Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway.

Authors:  K Nakatani; S Takeshita; H Tsujimoto; I Sekine
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

Review 2.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

3.  Impact of endothelin A receptor antagonist selectivity in chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat.

Authors:  Mark G Neerhof; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Hypertens Pregnancy       Date:  2010       Impact factor: 2.108

4.  Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1.

Authors:  Feng Dong; Xiaochun Zhang; Loren E Wold; Qun Ren; Zhaojie Zhang; Jun Ren
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

5.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Authors:  Longwei Qiao; Yuting Liang; Na Li; Xiaoxia Hu; Dongwei Luo; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 6.  Endothelium-derived ET-1 and the development of renal injury.

Authors:  Carmen De Miguel; David M Pollock; Jennifer S Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-05-20       Impact factor: 3.619

Review 7.  Role of endothelin-1 in hypertension.

Authors:  Marc Iglarz; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

8.  Generation and characterization of rendomab-B1, a monoclonal antibody displaying potent and specific antagonism of the human endothelin B receptor.

Authors:  Bertrand Allard; Anne Wijkhuisen; Aurélie Borrull; Frédérique Deshayes; Fabienne Priam; Patricia Lamourette; Frédéric Ducancel; Didier Boquet; Jean-Yves Couraud
Journal:  MAbs       Date:  2012-12-05       Impact factor: 5.857

9.  The endothelin system in Morris hepatoma-7777: an endothelin receptor antagonist inhibits growth in vitro and in vivo.

Authors:  Thiemo Pfab; Gisela Stoltenburg-Didinger; Christoph Trautner; Michael Godes; Christian Bauer; Berthold Hocher
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

10.  Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Authors:  Kari E Roberts; Ioana R Preston
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.